| 货号 | AF1103-SP |
| 别名 | CD321 antigen; CD321; F11 receptor; F11R; JAM-1; JAM1CD321; JAMA; JAM-A; JCAMJAM; Junctional adhesion molecule 1Platelet F11 receptor; junctional adhesion molecule A; PAM-1; PAM-1KAT; Platelet adhesion molecule 1 | 全称 | Junctional Adhesion Molecule A |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunohistochemistry(5-15 µg/mL) Immunocytochemistry(5-15 µg/mL) |
| 目标/特异性 | Detects human JAM-A in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 10% cross-reactivity with recombinant mouse JAM-A is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunohistochemistry: 5-15 µg/mL Immunocytochemistry: 5-15 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 50848 (Human); 16456 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human JAM-A Ser28-Ala242 Accession # Q9Y624 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | The family of junctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial or epithelial cells. Some family members are also found on blood leukocytes and platelets. Human JAM-A, also known as platelet adhesion molecule 1 (PAM-1) and platelet F11 receptor (3), is predominantly expressed at intercellular junctions of both epithelial cells and endothelial cells (1‑4). It is also expressed on circulating blood cells including neutrophils, monocytes, platelets, erythrocytes and lymphocytes (5). Human JAM-A cDNA predicts a 299 amino acid (aa) residue precursor protein with a putative 27 aa signal peptide, a 210 aa extracellular region containing two Ig‑like V-subset domains, a 24 aa transmembrane domain and a 38 aa cytoplasmic domain. The human and mouse proteins share approximately 67% aa sequence homology. Human JAM-A also shares approximately 35% and 32% aa sequence homology with human JAM-B and JAM-C, respectively. JAM-A exhibits homophilic interactions to regulate tight junction assembly and modulate paracellular permeability. This homophilic interation also mediates platelet aggregation and adhesion to endothelial cells and may play a role in thrombosis (3). JAM-A binds heterotypically with the beta 2 integrin lymphocyte function-associated antigen-1 (LFA-1). This JAM‑A‑LFA‑1 interaction is involved in leukocyte adhesion and transmigration (6). JAM-A has also been shown to bind reovirus attachment protein sigma-1 to permit reovirus infection and signal virus-induced apoptosis (7). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
JAM‑A in MCF‑7 Human Cell Line. JAM‑A was detected in immersion fixed MCF‑7 human breast cancer cell line using Goat Anti-Human JAM‑A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1103) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 493-conjugated Anti-Goat IgG Secondary Antibody (green; Catalog # NL003) and counterstained with DAPI (blue). Specific staining was localized to intercellular junctions. View our protocol for Fluorescent ICC Staining of Cells on Coverslips. |
